Oak Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Oak Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.55M	Sell	18,772 -2,969	-14%	-$519K	0.24%	61
2025 Q4	$3.7M	Sell	21,741 -354	-2%	-$54.3K	0.22%	52
2025 Q3	$2.91M	Hold	22,095	–	–	0.18%	64
2025 Q2	$2.34M	Hold	22,095	–	–	0.15%	68
2025 Q1	$2.74M	Sell	22,095 -200	-0.9%	-$26.1K	0.21%	58
2024 Q4	$2.75M	Hold	22,295	–	–	0.19%	59
2024 Q3	$2.48M	Buy	22,295 +8,950	+67%	+$981K	0.17%	66
2024 Q2	$1.42M	Hold	13,345	–	–	0.09%	91
2024 Q1	$1.61M	Buy	13,345 +5,808	+77%	+$711K	0.11%	90
2023 Q4	$927K	Sell	7,537 -11,092	-60%	-$1.38M	0.07%	101
2023 Q3	$2.41M	Buy	18,629 +3,512	+23%	+$468K	0.2%	64
2023 Q2	$1.87M	Buy	15,117 +1,370	+10%	+$184K	0.15%	78
2023 Q1	$2.01M	Buy	13,747 +10,092	+276%	+$1.49M	0.17%	79
2022 Q4	$582K	Sell	3,655 -17,122	-82%	-$2.51M	0.05%	126
2022 Q3	$2.77M	Hold	20,777	–	–	0.24%	59
2022 Q2	$3.24M	Buy	20,777 +2,727	+15%	+$420K	0.25%	58
2022 Q1	$2.81M	Hold	18,050	–	–	0.17%	65
2021 Q4	$2.3M	Hold	18,050	–	–	0.12%	78
2021 Q3	$2.35M	Hold	18,050	–	–	0.13%	74
2021 Q2	$3.21M	Hold	18,050	–	–	0.18%	63
2021 Q1	$2.97M	Buy	18,050 +5,100	+39%	+$839K	0.18%	64
2020 Q4	$2.14M	Buy	12,950 +9,295	+254%	+$1.38M	0.13%	76
2020 Q3	$521K	Hold	3,655	–	–	0.03%	104
2020 Q2	$403K	Hold	3,655	–	–	0.03%	109
2020 Q1	$365K	Hold	3,655	–	–	0.03%	107
2019 Q4	$546K	Hold	3,655	–	–	0.03%	120
2019 Q3	$468K	Hold	3,655	–	–	0.03%	123
2019 Q2	$521K	Hold	3,655	–	–	0.03%	124
2019 Q1	$522K	Hold	3,655	–	–	0.03%	124
2018 Q4	$453K	Hold	3,655	–	–	0.03%	127
2018 Q3	$615K	Buy	3,655 +690	+23%	+$119K	0.04%	128
2018 Q2	$511K	Hold	2,965	–	–	0.03%	131
2018 Q1	$448K	Buy	2,965 +1,320	+80%	+$194K	0.03%	132
2017 Q4	$221K	Buy	+1,645	New	+$228K	0.02%	153
2016 Q3	–	Sell	-1,500	Closed	-$212K	–	171
2016 Q2	$212K	Buy	+1,500	New	+$221K	0.03%	164
2016 Q1	–	Sell	-1,500	Closed	-$211K	–	164
2015 Q4	$211K	Buy	+1,500	New	+$208K	0.03%	166
2015 Q3	–	Sell	-1,500	Closed	-$264K	–	163
2015 Q2	$264K	Hold	1,500	–	–	0.03%	154
2015 Q1	$259K	Buy	+1,500	New	+$257K	0.03%	162

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Oak Associates's JAZZ Position: Q1 2026 in Review

Oak Associates reduced its Jazz Pharmaceuticals (JAZZ) stake by 14% in Q1 2026, selling an estimated $519K and leaving 18,772 shares worth $3.55M. The position accounts for 0.24% of the portfolio, ranked #61.

Oak Associates first reported a position in JAZZ in Q1 2015 and has held it in 38 quarters since. The position peaked at $3.7M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Oak Associates held 18,772 shares of Jazz Pharmaceuticals worth $3.55M as of Q1 2026.
Oak Associates sold 2,969 Jazz Pharmaceuticals shares in Q1 2026, an estimated $519K.
Jazz Pharmaceuticals made up 0.24% of Oak Associates's portfolio in Q1 2026, its #61 holding.
Oak Associates first reported a position in Jazz Pharmaceuticals in Q1 2015 and has held it in 38 quarters since.
Oak Associates's Jazz Pharmaceuticals position peaked at $3.7M in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Oak Associates's 13F filing for Q1 2026, filed 14 May 2026.